MedTrace Logo

The Covid-19 Outpatient Symptom Montelukast Oximetry Trial

NCT04389411 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2022-07-25

No results posted yet for this study

Summary

Primary care physicians face limited availability of therapeutic options for the treatment of COVID-19 in the outpatient setting. Furthermore, monoclonal antibodies and antiviral therapies that are currently approved for use in the outpatient setting by Health Canada have excluded pregnant women and older adults from their clinical trials, are contraindicated for many patients, and most are prohibited for use by pregnant women. Identification of a safe, COVID-19 outpatient therapeutic with 20-year safety record remains urgently needed.

Conditions

Interventions

DRUG

Montelukast 10mg

10mg oral Montelukast will be taken daily for 60 days

Sponsors & Collaborators

  • Segal Cancer Centre

    collaborator UNKNOWN

  • The McGill Practice Based Research Network

    collaborator UNKNOWN

  • Lady Davis Institute

    collaborator OTHER

  • McGill University

    lead OTHER

Principal Investigators

  • Machelle Wilchesky, PhD · Lady Davis Institute and McGill University

  • Geoffrey Tranmer, PhD · University of Manitoba

  • Roland Grad, MDCM MSc FCFP · Herzl Family Practice Centre and McGill University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-01-31
Completion
2025-02-28

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04389411 on ClinicalTrials.gov